DelveInsight’s, “Interstitial Cystitis (IC) – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Interstitial Cystitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Interstitial Cystitis Understanding
Interstitial Cystitis (IC): Overview
Interstitial cystitis (IC)/bladder pain syndrome (BPS) is a chronic bladder health issue. It is a feeling of pain and pressure in the bladder area. Along with this pain are lower urinary tract symptoms which have lasted for more than 6 weeks, without having an infection or other clear causes.
Currently there are two recognized subtypes of Interstitial cystitis: non-ulcerative and ulcerative.
• Non-ulcerative: 90% of IC patients have the non-ulcerative form of IC. Non-ulcerative Interstitial cystitis presents with pinpoint hemorrhages, also known as glomerulations, in the bladder wall. However, these are not specific for IC and any inflammation of the bladder can give that appearance.
• Ulcerative: 5 to 10% of IC patients have the ulcerative form of IC. These patients usually have Hunner’s ulcers or patches, which are red, bleeding areas on the bladder wall.
Symptoms
People with interstitial cystitis (IC) have repeat discomfort, pressure, tenderness or pain in the bladder, lower abdomen, and pelvic area. Symptoms vary from person to person, may be mild or severe, and can even change in each person as time goes on. Symptoms may include a combination of these symptoms:
• Urgency: With interstitial cystitis, the person may feel pain or burning along with an urgent need to urinate before the bladder has had time to fill.
• Frequency: Some people with IC feel a strong, painful urge to urinate many times a day.
• Pain: Pain from pelvic floor muscle spasm may get worse during sex.
Diagnosis
There’s no test for interstitial cystitis. Both men and women would first need to rule out urinary tract infections, bladder cancer, sexually transmitted diseases, and kidney stones. In women, endometriosis is another possibility. For men, interstitial cystitis can be mistaken for an inflamed prostate or chronic pelvic pain syndrome.
These tests can rule out other conditions:
• Urinalysis and urine culture
• Postvoid residual urine volume
• Cystoscopy
• Bladder and urethra biopsy
• Bladder stretching
• Prostate fluid culture
Treatment
There is no single treatment for interstitial cystitis (IC) that works for everyone. Doctors aim current treatments at relieving symptoms in each person on an individual basis. A health care professional will work with the patients to find a treatment plan that meets their needs. The plan may include:
• lifestyle changes
• bladder training
• physical therapy
• medicines
• bladder procedures
Interstitial Cystitis Emerging Drugs Chapters
This segment of the Interstitial Cystitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interstitial Cystitis Emerging Drugs
• AJOVY (Fremanezumab): Teva Pharmaceutical Industries
AJOVY, a humanized monoclonal antibodythat binds to calcitonin gene-related peptide (CGRP) ligand and blocksits binding to the receptor. Teva is conducting a multicenter, open-label pilot study of the efficacy and safety of fremanezumab for treatment of female patients with Interstitial Cystitis-Bladder Pain Syndrome. The primary objective of the study is to evaluate the efficacy of fremanezumab in reducing pain in patients with interstitial cystitis-bladder pain syndrome (IC-BPS).
• SI-722: Seikagaku Corporation
SI-722 is a novel chemical compound in which a steroid is conjugated with chondroitin sulfate using Seikagaku's proprietary glycosaminoglycan modification technology and drug delivery systems (DDS). SI-722 injected into the bladder is thought to demonstrate long-lasting improvement in the conditions of frequent urination and bladder pain by releasing a steroid with an anti-inflammatory effect. SI-722 has completed a Phase I clinical study in the U.S. In November 2019, it is starting a Phase II/II clinical study. This clinical study will evaluate the drug for safety, tolerability, and pharamcokinetics, and will conduct an exploratory evaluation of its effectiveness.
Further product details are provided in the report……..
Interstitial Cystitis: Therapeutic Assessment
This segment of the report provides insights about the different Interstitial Cystitis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Interstitial Cystitis
There are approx. 10+ key companies which are developing the therapies for Interstitial Cystitis. The companies which have their Interstitial Cystitis drug candidates in the mid stage, i.e., Phase II include, Astellas Pharma, Teva Pharmaceutical Industries etc.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Interstitial Cystitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Drug conjugates
• Monoclonal antibodies
• Proteins and Peptides

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interstitial Cystitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interstitial Cystitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interstitial Cystitis drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Interstitial Cystitis R&D. The therapies under development are focused on novel approaches to treat/improve Interstitial Cystitis
Interstitial Cystitis Report Insights
• Interstitial Cystitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Interstitial Cystitis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Interstitial Cystitis drugs?
• How many Interstitial Cystitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interstitial Cystitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interstitial Cystitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Interstitial Cystitis and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Teva Pharmaceutical Industries
• Seikagaku Corporation
Key Products
• Fremanezumab
• SI-722